Craft
Ionis Pharmaceuticals

Ionis Pharmaceuticals

Patents (US)

161

Jun, 2021

Revenue

$810.5 M

FY, 2021

Market Capitalization

$5.8 B

2023-01-20

Ionis Pharmaceuticals Summary

Company summary

Overview
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA), TEGSEDI, a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra, a medicine used to treat familial chylomicronaemia syndrome (FCS).
Type
Public
Status
Active
Founded
1989
HQ
Carlsbad, CA, US | view all locations
Website
http://www.ionispharma.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Brett P. Monia

    Brett P. Monia, Chief Executive Officer, Director

  • Onaiza Cadoret-Manier

    Onaiza Cadoret-Manier, Executive Vice President, Chief Product Strategy and Operations Officer

  • C. Frank Bennett

    C. Frank Bennett, Executive Vice President, Chief Scientific Officer

  • Eric E. Swayze

    Eric E. Swayze, Executive Vice President, Research

Operating MetricsView all

Manufacturing Facility Space, sq. ft.

26.8K
6.6%

FY, 2020

Phase I Trials Products

6
50.0%

FY, 2020

Phase II Trials Products

24
41.2%

FY, 2020

LocationsView all

1 location detected

  • Carlsbad, CA HQ

    United States

    2855 Gazelle Ct

Ionis Pharmaceuticals Financials

Summary financials

Revenue (Q3, 2022)
$159.8M
Gross profit (Q3, 2022)
$158.3M
Net income (Q3, 2022)
($47.0M)
Cash (Q3, 2022)
$315.0M
EBIT (Q3, 2022)
($59.2M)
Enterprise value
$5.5B

Footer menu